<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L18F;D80A;D215G;R246I;K417N;E484K;N501Y;D614G;A701V literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L18F;D80A;D215G;R246I;K417N;E484K;N501Y;D614G;A701V</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Mean 8.2x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.<br/> (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> DARPin SR16m molecule had a 0.036x fold change in IC50 in B.1.351 Beta (<a href="https://doi.org/10.1101/2022.05.30.493765" class="lit_link">Chonira et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> DARPin SR22 molecule had a 1.57x fold change in IC50 in B.1.351 Beta (<a href="https://doi.org/10.1101/2022.05.30.493765" class="lit_link">Chonira et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Trimeric proteins FSR16m had a 0.054x fold change in IC50 in B.1.351 Beta (<a href="https://doi.org/10.1101/2022.05.30.493765" class="lit_link">Chonira et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Trimeric proteins FSR22 had a 0.07x fold change in IC50 in B.1.351 Beta (<a href="https://doi.org/10.1101/2022.05.30.493765" class="lit_link">Chonira et al. (2022)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Log10ID50 of Beta neutralizing antibodies is 0.803x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5.<br/> (<a href="https://doi.org/10.1101/2022.06.24.22276144" class="lit_link">McEvoy C et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Log10ID50 of Beta neutralizing antibodies is 0.899x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5.<br/> (<a href="https://doi.org/10.1101/2022.06.24.22276144" class="lit_link">McEvoy C et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Paradigmâ€™s ACE-2 variant LVE/STR chimera neutralizes Beta Variant B.1.351 RBD significantly better than w.t. SARS-CoV-2 RBD. Determined using Surrogate Viral Neutralization Tests.<br/> (<a href="https://doi.org/10.1101/2022.06.23.497326" class="lit_link">Uhal B et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mean 6.3x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.<br/> (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
